

HEALTH BOARD

HIGHLIGHT REPORT – EXTRA ORDINARY PLANNING, PERFORMANCE & FINANCE IN COMMITTEE

DATE OF MEETING	29/09/2022
------------------------	------------

PUBLIC OR PRIVATE REPORT	Public
---------------------------------	--------

IF PRIVATE PLEASE INDICATE REASON	Not Applicable - Public Report
--	--------------------------------

PREPARED BY	Kathrine Davies, Corporate Governance Manager
--------------------	---

PRESENTED BY	Mel Jehu, Independent Member (Committee Chair
---------------------	---

EXECUTIVE SPONSOR APPROVED	Director of Strategy and Transformation, Chief Operating Officer, Director of Finance
-----------------------------------	---

REPORT PURPOSE	FOR NOTING
-----------------------	------------

ACRONYMS	
IMTP	Integrated Medium Term Plan
ILG	Integrated Locality Groups
PPF	Planning, Performance & Finance

1. INTRODUCTION

- 1.1 This paper had been prepared to provide the Board with details of the key issues considered by the Extra Ordinary Planning, Performance & Finance 'In Committee' meeting which took place on 20 September 2022.

- 1.2 Key highlights from the meeting are contained in section 2.
- 1.3 The Board are requested to **NOTE** the contents of the report and support the recommendation of the Committee.

2. PURPOSE OF THE PLANNING, PERFORMANCE & FINANCE COMMITTEE

The Committee will allow appropriate scrutiny and review to a level of depth and detail not possible in Board meetings in respect of planning, performance and finance. The Committee will ensure that evidence based and timely interventions are implemented to drive forward improved performance thereby allowing the Health Board to achieve the requirements and standards determined for the NHS in Wales, and as outlined within the Board's 3 Year Integrated Medium Term Plan.

An extra-ordinary meeting of the committee was convened in private session (in-committee) to consider and scrutinise a business case that contains commercially sensitive information.

3. HIGHLIGHT REPORT

ALERT / ESCALATE	<ul style="list-style-type: none"> • Nil this period.
ADVISE	<ul style="list-style-type: none"> • The Committee received a report on the Integrated Radiotherapy Solution and Satellite Radiotherapy Centre Full Business Case. The Committee at their August 2022 meeting had agreed to hold a further Extra Ordinary In Committee in order to receive further details on the two Business Cases that had been approved by the Executive Leadership Group at their meeting held on the 12th September 2022 and would further be considered by the Board at its meeting on the 29th September 2022. The Committee noted the Health Boards contribution to the revenue costs which were recurrent and endorsed the two Full Business Cases for Board Approval at the meeting on 29th September 2022.



ASSURE	
INFORM	
APPENDICES	NOT APPLICABLE